© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Scholar Rock Holding Corporation (SRRK) stock declined over -4.88%, trading at $54.62 on NASDAQ, down from the previous close of $57.42. The stock opened at $57.26, fluctuating between $54.44 and $57.38 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 09, 2026 | 57.30 | 57.65 | 54.44 | 54.62 | 1.6M |
| Sep 08, 2026 | 54.09 | 57.79 | 54.00 | 57.42 | 1.66M |
| Sep 04, 2026 | 55.08 | 55.98 | 55.00 | 55.33 | 658.03K |
| Sep 03, 2026 | 56.14 | 56.24 | 55.00 | 55.94 | 803.22K |
| Sep 02, 2026 | 56.62 | 58.10 | 55.27 | 56.10 | 1.07M |
| Sep 01, 2026 | 56.45 | 57.70 | 55.33 | 55.89 | 762.24K |
| Aug 31, 2026 | 57.20 | 57.82 | 56.10 | 56.80 | 987.26K |
| Aug 28, 2026 | 58.75 | 59.30 | 57.17 | 57.80 | 809.72K |
| Aug 27, 2026 | 60.00 | 60.18 | 58.87 | 59.26 | 620.68K |
| Aug 26, 2026 | 58.25 | 61.76 | 57.61 | 60.04 | 2.28M |
| Aug 25, 2026 | 58.20 | 59.48 | 57.06 | 58.25 | 1.21M |
| Aug 24, 2026 | 56.80 | 58.75 | 55.90 | 58.20 | 1.22M |
| Aug 21, 2026 | 55.38 | 57.10 | 54.98 | 56.50 | 1.16M |
| Aug 20, 2026 | 55.93 | 56.75 | 54.84 | 55.25 | 1.33M |
| Aug 19, 2026 | 56.13 | 57.15 | 54.09 | 56.51 | 1.33M |
| Aug 18, 2026 | 51.91 | 54.78 | 51.91 | 54.72 | 1.22M |
| Aug 17, 2026 | 52.00 | 52.97 | 51.82 | 52.05 | 778.67K |
| Aug 14, 2026 | 52.94 | 52.97 | 51.50 | 52.52 | 496.6K |
| Aug 13, 2026 | 54.84 | 55.00 | 52.68 | 53.06 | 942.94K |
| Aug 12, 2026 | 52.18 | 54.70 | 51.85 | 53.82 | 899.24K |
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
| Employees | 289 |
| Beta | 0.67 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |